Ligands for the nuclear receptor superfamily control many aspects of biology, including
development, reproduction, and homeostasis, through regulation of the transcriptional …

Estrogens play an important role in regulating the growth and differentiation of normal,
premalignant and malignant cell types, especially breast epithelial cells, through interaction …

Background: The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation
(MORE) trial found that 4 years of raloxifene therapy decreased the incidence of invasive …

ContextA family history of certain cancers is associated with an increased risk of developing
cancer. Both cancer screening and genetic services referral decisions are often based on …

Tamoxifen is one of the most effective treatments for breast cancer through its ability to
antagonize estrogen-dependent growth by binding estrogen receptors (ERs) and inhibiting …

BACKGROUND Tamoxifen therapy for patients with breast carcinoma is perceived as an
independent risk factor for venous thromboembolic events (VTE), but the risk associated with …

Molecular Biology of Cancer has been extensively revised and covers heredity cancer,
microarray technology and increased study of childhood cancers. It continues to provide a …

A central epidemiological feature of cancers of the breast, endometrium and ovary is the
sharp slowing down in their rate of increase with age around the time of menopause. The …

In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7705 postmenopausal
women with osteoporosis, defined by low bone mineral density and/or prevalent vertebral …

Background: Tamoxifen reduces the risk for contralateral breast cancer by approximately
30%–50%, with benefits probably limited to women with estrogen receptor (ER)-positive …